Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
David M. O’shaughnessy, Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai, Frances Quirk
Therapeutic Advances in Psychopharmacology 2021 DOI: 10.1177/2045125320986634 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 36 |
| Population | Male inpatients in a residential addiction treatment center in Tarapoto, Peru |
| Intervention | combination of Western and traditional Amazonian methods |
| Duration | At least 2 months for neuropsychological assessment; repeated measures throughout treatment |
| Topics | Addiction |
| Key findings | Statistically significant and clinically positive changes were found across all repeated measures of perceived stress, craving frequency, mental illness symptoms, spiritual well-being, and physical and emotional health, as well as in neuropsychological functioning. |
Abstract
Aims: The therapeutic use of psychedelics is regaining scientific momentum, but similarly psychoactive ethnobotanical substances have a long history of medical (and other) uses in indigenous contexts. Here we aimed to evaluate patient outcomes in a residential addiction treatment center that employs a novel combination of Western and traditional Amazonian methods.
Methods: The study was observational, with repeated measures applied throughout treatment. All tests were administered in the center, which is located in Tarapoto, Peru. Data were collected between 2014 and 2015, and the study sample consisted of 36 male inpatients who were motivated to seek treatment and who entered into treatment voluntarily. Around 58% of the sample was from South America, 28% from Europe, and the remaining 14% from North America. We primarily employed repeated measures on a psychological test battery administered throughout treatment, measuring perceived stress, craving frequency, mental illness symptoms, spiritual well-being, and physical and emotional health. Addiction severity was measured on intake, and neuropsychological performance was assessed in a subsample from intake to at least 2 months into treatment.
Results: Statistically significant and clinically positive changes were found across all repeated measures. These changes appeared early in the treatment and were maintained over time. Significant improvements were also found for neuropsychological functioning.
Conclusion: These results provide evidence for treatment safety in a highly novel addiction treatment setting, while also suggesting positive therapeutic effects.
Comparable studies
Other observational and cohort studies on addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Dynamic coupling of whole-brain neuronal and neurotransmitter systems Healthy humans | 2020 | Observational study | |
| Psychedelics not linked to mental health problems or suicidal behavior: A population study Randomly selected United States adults | 2015 | Observational cohort | n = 135,095 |
| Breakdown of long-range temporal dependence in default mode and attention networks during deep sleep Human participants across the nonrapid eye movement sleep cycle | 2013 | Observational cohort | |
| Assessment of addiction severity among ritual users of ayahuasca Regular ayahuasca users (jungle-based and urban-based) and matched controls | 2010 | Observational cohort | n = 127 |
Citations in the library
Cited by 27
- Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research Addiction Neuroscience June 22, 2022
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences September 10, 2024
- The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. Psychedelic Medicine June 1, 2023
- Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review Addiction January 30, 2025
- Quality of reporting on psychological interventions in psychedelic treatments: a systematic review. The Lancet Psychiatry 2025
and 22 more in the library
Cites 76
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
and 71 more in the library